Neurologic - Sanofi

Neurologic

Status:

Open/Enrolling

ClinicalTrials.gov:

NCT06290141

A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Drug

riliprubart

Phase

Phase III

Condition

Chronic Inflammatory Demyelinating Polyneuropathy, CIDP

Keywords

Chronic Inflammatory Demyelinating Polyneuropathy | CIDP